Search results for "Amides"

showing 10 items of 552 documents

Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.

2004

The endogenous ligands of cannabinoid receptors, also known as endocannabinoids, have been implicated in many physiological and pathological processes of the central nervous system. Here we show that the levels of the two major endocannabinoids, anandamide and 2-arachidonoyl-glycerol (2-AG), in four areas of the rat brain, change dramatically between the light and dark phases of the day. While anandamide levels in the nucleus accumbens, pre-frontal cortex, striatum and hippocampus were significantly higher in the dark phase, the opposite was observed with 2-AG, whose levels were significantly higher during the light phase in all four regions. We found that the activity of the fatty acid ami…

Malemedicine.medical_specialtyDiacylglycerol lipaseCannabinoid receptorPolyunsaturated Alkamidesmedicine.medical_treatmentPhotoperiod2-ArachidonoylglycerolArachidonic AcidsAmidohydrolasesGlyceridesRats Sprague-DawleyCellular and Molecular Neurosciencechemistry.chemical_compoundFatty acid amide hydrolaseInternal medicineCannabinoid Receptor ModulatorsmedicineanandamideAnimals2-arachidonoylglycerol; anandamide; cannabinoid; circadian; faahMolecular BiologyPharmacologybiologyBrainCell BiologyAnandamidefaahcannabinoidEndocannabinoid system2-arachidonoylglycerolCircadian RhythmRatsMonoacylglycerol lipaseEndocrinologycircadianchemistryBiochemistrybiology.proteinMolecular MedicineCannabinoidEndocannabinoidsCellular and molecular life sciences : CMLS
researchProduct

Gastrointestinal stromal tumour of the rectum: Report of a case and review of literature

2008

Gastrointestinal stromal tumour (GIST) is a rare tumour of the gastrointestinal tract which does not generally originate in the rectum. The authors describe a case of a 70-year-old man who underwent an anterior resection of the rectum for a low-risk GIST. The patient was not given adjuvant chemotherapy with imatinib and is still disease-free 30 mo after surgery. The authors conclude that although rectal GIST is extremely uncommon, it should be included in differential diagnosis when a tumour in the rectum is detected. Biopsy of the tumour is essential, since this makes it possible to reach a sure preoperative diagnosis based on the immunohistological features of the CD117 and CD34. Although…

Malemedicine.medical_specialtyGastrointestinal Stromal TumorsCD34RectumAntigens CD34Antineoplastic AgentsCase ReportPiperazinesGIST;BiopsymedicineHumansneoplasmsAgedGastrointestinal tractGiSTmedicine.diagnostic_testbiologyRectal NeoplasmsCD117business.industryGastroenterologyGeneral MedicineCombined Modality Therapydigestive system diseasesSurgeryProto-Oncogene Proteins c-kitPyrimidinesTreatment Outcomemedicine.anatomical_structureImatinib mesylateBenzamidesImatinib Mesylatebiology.proteinDifferential diagnosisbusinessGISTWorld Journal of Gastroenterology
researchProduct

HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?

2014

BACKGROUND: The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection. In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis. METHODS: In this multicenter, randomized, double-blind, placebocontrolled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-ta…

Malemedicine.medical_specialtyMacrocyclic CompoundsDirect-acting antiviralsLiver functionGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePegylated interferonInternal medicineRibavirinmedicineHumansAnilidesPortal hypertensionUracilAdvanced liver diseaseSulfonamidesDasabuvirRitonavirHepatologybusiness.industryRibavirinvirus diseasesHepatitis C ChronicVirologyOmbitasvir3. Good healthRegimenchemistryParitaprevir030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRitonavirFemaleLiver functionCarbamatesbusinessmedicine.drugJournal of Hepatology
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Endocannabinoid Levels in Newborns in Relation to the Mode of Delivery.

2015

Objective  This study aims to examine the endocannabinoid levels in newborns in relation to the mode of delivery. Study Design  In this study, the concentrations of the endocannabinoids anandamide (AEA), 2-arachidonylglycerol (2-AG), palmitoylethanolamine (PEA), and the metabolite arachidonic acid (AA) in umbilical cord vein blood of 49 newborns was determined by quantitative mass spectrometry using liquid chromatography multiple reaction monitoring. The newborns were divided by their mode of delivery. Only healthy newborns born after 34 0/7 gestational weeks without birth complications were included. Results  The concentration of AEA, PEA, and AA was significantly higher in vaginal deliver…

Malemedicine.medical_specialtyPolyunsaturated AlkamidesMetaboliteArachidonic AcidsMass SpectrometryGlycerideschemistry.chemical_compoundInternal medicineMedicineEndocrine systemHumansFetusbusiness.industryVaginal deliveryInfant NewbornObstetrics and GynecologyAnandamideDelivery ObstetricEndocannabinoid systemMode of deliveryEndocrinologychemistryAnesthesiaPediatrics Perinatology and Child Healthlipids (amino acids peptides and proteins)Arachidonic acidFemalebusinessChromatography LiquidEndocannabinoidsAmerican journal of perinatology
researchProduct

Alterations in the Hippocampal Endocannabinoid System in Diet-Induced Obese Mice

2010

The endocannabinoid (eCB) system plays central roles in the regulation of food intake and energy expenditure. Its alteration in activity contributes to the development and maintenance of obesity. Stimulation of the cannabinoid receptor type 1 (CB1receptor) increases feeding, enhances reward aspects of eating, and promotes lipogenesis, whereas its blockade decreases appetite, sustains weight loss, increases insulin sensitivity, and alleviates dysregulation of lipid metabolism. The hypothesis has been put forward that the eCB system is overactive in obesity. Hippocampal circuits are not directly involved in the neuronal control of food intake and appetite, but they play important roles in hed…

Malemedicine.medical_specialtyPolyunsaturated Alkamidesmedicine.medical_treatmentmedia_common.quotation_subjectArachidonic AcidsBiologyHippocampusArticlegamma-Aminobutyric acidGlyceridesMice03 medical and health sciences0302 clinical medicineReceptor Cannabinoid CB1Internal medicineCannabinoid Receptor ModulatorsCannabinoid receptor type 1medicineAnimalsObesityReceptorgamma-Aminobutyric Acid030304 developmental biologymedia_commonMice KnockoutNeurons0303 health sciencesLong-Term Synaptic DepressionGeneral NeuroscienceAppetiteDietary FatsEndocannabinoid systemMice Inbred C57BLDisease Models AnimalLipoprotein LipaseEndocrinologynervous systemSynapsesSynaptic plasticitylipids (amino acids peptides and proteins)CannabinoidDiet-induced obese030217 neurology & neurosurgeryEndocannabinoidsmedicine.drugThe Journal of Neuroscience
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercho…

2013

Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease risk with low-density lipoprotein cholesterol (LDL-C) levels ≥100 and ≤160 mg/dl while treated with atorvastatin 10 mg/day entered a multicenter, randomized, double-blind, active-controlled, clinical trial using two 6-week study periods. Period I compared the efficacy/safety of (1) adding ezetimibe 10 mg (ezetimibe) to stable atorvastatin 10 mg, (2) doubling atorvastatin to 20 mg, or (3) switching to rosuvastatin 10 mg. Subjects in the latter 2 groups who persisted with elevated LDL-C levels (≥100 and ≤160 mg/dl) after period I, entered period II; subjects on atorvastatin 20 mg had ezetimibe added to th…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAtorvastatinHypercholesterolemiaUrologylaw.inventionchemistry.chemical_compoundEzetimibeRandomized controlled trialDouble-Blind Methodlawhealth services administrationInternal medicineprimary hypercholesterolemiaatorvastatin; ezetimibe; rosuvastatin; primary hypercholesterolemiamedicineAtorvastatinHumansRosuvastatinIn patientPyrrolescardiovascular diseasesRosuvastatin CalciumAgedSulfonamidesCholesterolbusiness.industryAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLMiddle AgedEzetimibeClinical trialFluorobenzenesRosuvastatin CalciumLogistic ModelsPyrimidineschemistryHeptanoic AcidsCardiologyAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessrosuvastatinmedicine.drugThe American journal of cardiology
researchProduct

Epidural ropivacaine -- where are the benefits? A prospective, randomized, double-blind trial in patients with retropubic prostatectomy.

2007

Background:  In comparison with bupivacaine, ropivacaine exhibits comparable anaesthetic effects but with less motor impairment and systemic toxicity. However, the analgesic potency may differ. For example, ropivacaine during obstetric epidural analgesia provides an approximately 40% lower analgesic potency than bupivacaine. Equal visual analogue pain scores require significantly higher dosages of ropivacaine, and general statements about a favourable benefit–risk profile relative to that of bupivacaine may therefore have limited clinical impact. We addressed this topic in a male pain model by evaluating the analgesic efficacy of epidural ropivacaine 0.2% vs. bupivacaine 0.125% after retrop…

Malemedicine.medical_specialtyTime FactorsDosemedicine.drug_classAnalgesicMotor ActivityStatistics NonparametricLumbarDouble-Blind MethodClinical endpointmedicineHumansRopivacaineProspective StudiesEpidural administrationAnesthetics LocalAgedPain MeasurementBupivacaineProstatectomyPain Postoperativebusiness.industryRopivacaineLocal anestheticAnalgesia Patient-ControlledGeneral MedicineMiddle AgedAmidesBupivacaineSurgeryAnalgesia EpiduralAnesthesiology and Pain MedicinePatient SatisfactionAnesthesiabusinessmedicine.drugActa anaesthesiologica Scandinavica
researchProduct

Comparison between local and regional anesthesia in arteriovenous fistula creation.

2011

Purpose Assessment of the effectiveness of Brachial Plexus Block (BPB) via axillary approach compared to regional anesthesia for arteriovenous fistula surgery in patients affected by end-stage renal disease. Methods We compared forty patients randomly divided into two groups. Group A underwent BPB procedure with 15 mL ropivacaine 1% and 10 mL of saline (0.9% NaCl) via axillary approach. Group B received local anesthesia with lidocaine 2%. The forearm blood vessels were assessed by Doppler ultrasonography before and after the intervention. Results BPB performed on Group A was associated with a considerable venous dilation and a significant decrease (48.7%, P<.05) in pulsatility index (PI)…

Malemedicine.medical_specialtyTime Factorslocal and regional anesthesiaFistulaArteriovenous fistulaSettore MED/41 - AnestesiologiaVeinsArteriovenous Shunt SurgicalForearmRenal DialysisOcclusionmedicineHumansLocal anesthesiaBrachial PlexusRopivacaineAnesthetics Localarteriovenous fistulaBrachial plexus blockarteriovenous fistula; local and regional anesthesiaAgedRopivacainebusiness.industryLidocaineNerve BlockUltrasonography DopplerMiddle Agedmedicine.diseaseThrombosisAmidesSurgeryVasodilationSettore MED/18 - Chirurgia GeneraleForearmmedicine.anatomical_structureTreatment OutcomeItalyNephrologyAnesthesiaRadial ArteryKidney Failure ChronicSurgeryFemalebusinessmedicine.drugAnesthesia LocalThe journal of vascular access
researchProduct